ESMO 2018 - Results from #40

Viewing 41-60 of 96 articles

ESMO 2018: Overall Survival Results – RANGE, Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma

ESMO 2018: Tumor Molecular Characteristics in Patients with International Metastatic Renal Cell Carcinoma Database Consortium- Good and Intermediate/Poor Risk

ESMO 2018: Cancer Awareness and Screening: The Challenges

ESMO 2018: Comprehensive Genomic Profiling of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors

ESMO 2018: LATITUDE: PSA Response Characteristics and Correlation with Overall Survival and Radiological Progression-Free Survival

ESMO 2018: Why We are Losing the War on Cancer

ESMO 2018: Preliminary Results From TRITON2: A Phase II Study of Rucaparib in Patients with mCRPC Associated with Homologous Recombination Repair Gene Alterations

ESMO 2018: Comprehensive Biomarker Analyses and Updated Results of PURE-01 Study: Neoadjuvant Pembrolizumab in Muscle-Invasive Urothelial Bladder Carcinoma

ESMO 2018: Is There Still a Role for Chemotherapy in Bladder Cancer?

ESMO 2018: Neoadjuvant Therapy with Pembrolizumab Alone or in Combination with Cisplatin plus Gemcitabine for Locally Advanced Urothelial Cancer, A Phase Ib/2 Study

ESMO 2018: Abundance of Riches in View of Health Care Constraints

ESMO 2018: Efficacy and Safety of Axitinib in Metastatic Papillary Renal Carcinoma: Results of GETUG, a Multicenter Phase II Trial

ESMO 2018: The Current Use of TKI in Renal Cancer

ESMO 2018: Assessment of Renal Cell Carcinoma Asymptomatic Brain Metastases Patients from GETUG-AFU 26 (NIVOREN) Trial

ESMO 2018: The Role of PD-L1 Status as A Predictor or Prognostic Marker of Clinical Outcomes in Patients Treated on CABOSUN and METEOR

ESMO 2018: RANGE, A Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma: Overall Survival Results

ESMO 2018: A Phase Ib/2 Study of Neoadjuvant Pembrolizumab and Chemotherapy for Locally Advanced Urothelial Cancer

ESMO 2018: The Surgical Approach for Malignant Pheochromocytoma / Paraganglioma

ESMO 2018: Pillars of an Effective Healthcare System in Europe, Special Focus on Healthcare in Central and Eastern Europe

ESMO 2018: Venous Thromboembolism in Cancer

1
2
3
4
5